AUTHORS
Ashutosh D. Wechalekar, MD, Hans C Lee, MD2, Giovanni Palladini, MD,PhD3, Jeffrey A. Zonder, MD4, Mahmoud R. Gaballa, MD5, Kihyun Kim6, Henning Schade7, Natalia Tovar, MD8, Youngil Koh, MD9, Javier De La Rubia, MD, PhD10, Chang-Ki Min, MD, PhD11, Oluwaseun Aina, MD12, Anasuya Hazra, PhD13, Benny Ren14, Christopher J. Gamper, MD, PhD15, Elisabet Manasanch16, Anita Boyapati, PhD17, Shawn Sarkaria, MD18, Efstathios Kastritis19
AFFILIATIONS
1 University College London Hospitals and National Amyloidosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom
2 Sarah Cannon Research Institute, Nashville, Tennessee, United States
3 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
4 Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States
6 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South
7 Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, Colorado, United States
8 Amyloidosis and Myeloma Unit, Hospital Clínic Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
9 Cancer Research Institute, Seoul National University, Seoul, Korea, Rep. of South, Seoul National University College of Medicine, Seoul, Korea, Rep. of South
10 Hospital Universitari i Politècnic La Fe, Universidad Católica de Valencia San Vicente Mártir, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
11 Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Rep. of South
12 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
13 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
14 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
15 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
16 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
17 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
18 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
19 Alexandra Hospital, University of Athens, Athens, Greece, National and Kapodistrian University of Athens, Athens, Greece
ABSTRACT
Introduction
Systemic immunoglobin AL amyloidosis is a clonal plasma cell disorder characterized by deposition of pathogenic amyloid free light chains (FLCs) in vital organs, resulting in organ dysfunction, organ failure, and death. Currently no treatments are approved for AL amyloidosis beyond first-line therapy. Linvoseltamab is a B-cell maturation antigen (BCMA)xCD3 bispecific antibody designed to engage plasma cells and T cells, leading to plasma cell depletion and reduced FLC production/deposition, enabling preservation and recovery of organ function. The Phase 1/2 LINKER-AL2 study (NCT06292780) assesses linvoseltamab monotherapy in RR AL amyloidosis. Initial results from the Phase 1 portion of the study (median follow-up of 9.5 months, data as of April 22, 2026, as presented at EHA 2026) have shown no dose-limiting toxicities (DLTs), a generally manageable safety profile, and encouraging efficacy. In this abstract, we report additional data on T cell activation by serum cytokine markers, involved FLC (iFLC) reduction kinetics, and minimal residual disease (MRD) in the bone marrow based on the same data cutoff. Updated data with longer follow-up as of August 2026 will be included in the ASH presentation.
Methods
Eligible adults with RR systemic AL amyloidosis who had received ≥1 prior therapy were treated with linvoseltamab intravenous (IV) step-up doses (5 mg, 25 mg) followed by subcutaneous full doses (80 or 240 mg) in 28-day cycles (C): Q1W (C1–2) and Q4W (C3–24). The Phase 1 primary endpoint was incidence of DLTs within 28 days post-first full dose. Secondary endpoints included safety, rates of hematologic responses (including complete response [hCR]), time to hematologic responses, and assessment of organ involvement and response by the International Society of Amyloidosis response criteria. Exploratory endpoints included MRD by EuroFlow (assessed in patients who achieved hCR) and serum cytokines including IL-2 and IFN-gamma (assessed over time as markers of T cell engagement).
Results
In Phase 1, 20 patients were treated with linvoseltamab (80 mg, n=7; 240 mg, n=13). Transient induction of IFN-gamma and IL-2, reflective of T cell activation, occurred predominantly during IV step-up dosing. The elevation of serum cytokines was not dose dependent or higher in patients with CRS (10 patients; Gr1 n=7, Gr2 n=3, 9/10 during step-up dosing) or ICANS (1 patient; Gr1).
In efficacy assessment, linvoseltamab demonstrated high hCR rates (80 mg, 71%; 240 mg, 100%; all patients, 90%); VGPR or greater was achieved in 100% of patients. Mean serum concentration of iFLC decreased rapidly after treatment, reaching <10 mg/L at a median of 2.5 weeks (within 1 week after the first linvoseltamab full dose). Mean serum iFLC levels further decreased to at or below the lower limit of quantification during C2 and beyond. Organ response was achieved in 50% (4/8) and 73% (8/11) of patients evaluable for cardiac and renal responses, respectively. Of 6 patients who achieved hCR and were evaluable for MRD negativity, all achieved MRD-negative status at a 10-5 threshold.
Conclusion
In Phase 1 of LINKER-AL2, linvoseltamab monotherapy demonstrated rapid and high rates of hCR and organ responses, rapid iFLC reduction, and generally manageable safety. All patients with hCR who were MRD evaluable achieved MRD negativity at 10-5. T cell activation was observed in step-up dosing and was not dose or adverse event related. The Phase 2 portion is ongoing with registrational intent.
DISCLOSURES
Ashutosh D. Wechalekar, MD: Janssen-Cilag - Honoraria; Alexion Pharmaceuticals - Honoraria; Prothena - Honoraria; Attralus - Consultancy (Includes expert testimony); Alexion Pharmaceuticals - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony)